ID: ALA260120

Max Phase: Preclinical

Molecular Formula: C25H33N5O5

Molecular Weight: 483.57

Molecule Type: Protein

Representations

Canonical SMILES:  C[C@H](C(=O)N[C@@H](Cc1ccccc1)C(=O)N(C)CC(N)=O)N(C)C(=O)[C@@H](N)Cc1ccc(O)cc1

Standard InChI:  InChI=1S/C25H33N5O5/c1-16(30(3)24(34)20(26)13-18-9-11-19(31)12-10-18)23(33)28-21(14-17-7-5-4-6-8-17)25(35)29(2)15-22(27)32/h4-12,16,20-21,31H,13-15,26H2,1-3H3,(H2,27,32)(H,28,33)/t16-,20+,21+/m1/s1

Standard InChI Key:  GRHNSLXBGRDMSP-CZAAIQMYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Protein

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 483.57

Molecular Weight (Monoisotopic): 483.2482

AlogP: -0.22

#Rotatable Bonds: 11

Polar Surface Area: 159.06

Molecular Species: NEUTRAL

HBA: 6

HBD: 4

#RO5 Violations: 0

HBA (Lipinski): 10

HBD (Lipinski): 6

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 9.50

CX Basic pKa: 7.72

CX LogP: -0.25

CX LogD: -0.60

Aromatic Rings: 2

Heavy Atoms: 35

QED Weighted: 0.35

Np Likeness Score: -0.25

References

1. Ballet S, Misicka A, Kosson P, Lemieux C, Chung NN, Schiller PW, Lipkowski AW, Tourwé D..  (2008)  Blood-brain barrier penetration by two dermorphin tetrapeptide analogues: role of lipophilicity vs structural flexibility.,  51  (8): [PMID:18370374] [10.1021/jm701404s]

2. Vandormael B, Fourla DD, Gramowski-Voss A, Kosson P, Weiss DG, Schröder OH, Lipkowski A, Georgoussi Z, Tourwé D..  (2011)  Superpotent [Dmt¹] dermorphin tetrapeptides containing the 4-aminotetrahydro-2-benzazepin-3-one scaffold with mixed μ/δ opioid receptor agonistic properties.,  54  (22): [PMID:21978284] [10.1021/jm200894e]

Source

Source(1):

• Scientific Literature